Autoimmune encephalitis in Intensive Care Unit: A Review Article

Ashraf Alsawareah; Omar Yousef; Omar Ismail; Ahmad Hanandeh; Razan Aburumman; Ahmad Mahadeen

doi:10.58877/japaj.v2i1.117

Authors

Ashraf Alsawareah
Omar Yousef
Omar Ismail University of Jordan
Dr. Ahmad Hanandeh
Dr. Razan Aburuman
Dr. Ahmad Mahadeen

DOI:

https://doi.org/10.58877/japaj.v2i1.117

Abstract

Background: Autoimmune encephalitis (AE) is a group of immunologic diseases affecting the central nervous system (CNS). It is now considered a common cause of encephalitis and often requires intensive care unit (ICU) level care.

Aims: This review aims to provide intensivists with a toolkit to better recognize, diagnose, and manage patients with AE in the ICU.

Sources: A search of online databases using relevant keywords yielded papers discussing the epidemiology, diagnosis, management, and outcome of AE in the ICU setting.

Content: Due to the development of new antibody testing toolkits, the prevalence of AE has been on the rise during the past few decades. Timely recognition and diagnosis of AE in the ICU can significantly improve patient outcomes. Diagnostic criteria help classify patients into possible, probable, or definite AE categories based on clinical and paraclinical findings.

Management of AE involves immunomodulatory and immunosuppressive therapies, along with targeting associated neoplastic processes or triggers. First-line treatments include corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange (PLEX), while second-line therapies may be required for refractory cases.

AE can result in seizures, movement disorders, dysautonomia, respiratory failure, altered mental status, and psychosis. These complications require a combination of immunotherapy and symptomatic treatment for effective management. Prognosis varies but timely and appropriate management significantly improves outcomes.

Keywords: Autoimmune Encephalitis, ICU, Intensive Care, Diagnosis, Management, Prognosis

References

Hiesgen J, Schutte CM. Autoimmune encephalitis: Epidemiology, pathophysiology and clinical spectrum (part 1). South African Med J. 2023; DOI: https://doi.org/10.7196/SAMJ.2023.v113i4.875

Greenfield JG. Subacute spino-cerebellar degeneration occurring in elderly patients. Brain. 1934; DOI: https://doi.org/10.1093/brain/57.2.161

Leypoldt F, Wandinger KP, Bien CG, Dalmau J. Autoimmune encephalitis. Eur Neurol Rev. 2013;

Bloch KC, Glaser CA. Encephalitis surveillance through the emerging infections program, 1997–2010. Emerg Infect Dis. 2015; DOI: https://doi.org/10.3201/eid2109.150295

Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018; DOI: https://doi.org/10.1002/ana.25131

Yeshokumar AK, Gordon-Lipkin E, Arenivas A, Cohen J, Venkatesan A, Saylor D, et al. Neurobehavioral outcomes in autoimmune encephalitis. J Neuroimmunol. 2017; DOI: https://doi.org/10.1016/j.jneuroim.2017.08.010

Harutyunyan G, Hauer L, Dünser MW, Karamyan A, Moser T, Pikija S, et al. Autoimmune Encephalitis at the Neurological Intensive Care Unit: Etiologies, Reasons for Admission and Survival. Neurocrit Care. 2017; DOI: https://doi.org/10.1007/s12028-016-0370-7

Varvat J, Lafond P, Page Y, Coudrot M, Reynaud-Salard M, Tardy B. Acute psychiatric syndrome leading young patients to ICU: Consider anti-NMDA-receptor antibodies. Anaesth Intensive Care. 2010; DOI: https://doi.org/10.1177/0310057X1003800420

De Montmollin E, Demeret S, Brulé N, Conrad M, Dailler F, Lerolle N, et al. Anti-N-methyl-D-aspartate receptor encephalitis in adult patients requiring intensive care. Am J Respir Crit Care Med. 2017; DOI: https://doi.org/10.1164/rccm.201603-0507OC

Chen X, Li JM, Liu F, Wang Q, Zhou D, Lai X. Anti-N-methyl-d-aspartate receptor encephalitis: a common cause of encephalitis in the intensive care unit. Neurol Sci. 2016; DOI: https://doi.org/10.1007/s10072-016-2702-y

Harutyunyan G, Hauer L, Dünser MW, Moser T, Pikija S, Leitinger M, et al. Risk factors for intensive care unit admission in patients with autoimmune encephalitis. Front Immunol. 2017; DOI: https://doi.org/10.3389/fimmu.2017.00835

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016. DOI: https://doi.org/10.1016/S1474-4422(15)00401-9

M.K. M, A.A. R, S.E. H, S.J. P, E.F. MW, A. M. Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes. Neurocrit Care. 2016;

Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012; DOI: https://doi.org/10.1002/ana.23689

Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, et al. Autoimmune Encephalitis Misdiagnosis in Adults. JAMA neurology. 2023. DOI: https://doi.org/10.1001/jamaneurol.2022.4251

Lancaster E. The diagnosis and treatment of autoimmune encephalitis. Journal of Clinical Neurology (Korea). 2016. DOI: https://doi.org/10.3988/jcn.2016.12.1.1

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol. 2013; DOI: https://doi.org/10.1016/S1474-4422(12)70310-1

Shin YW, Lee ST, Park K Il, Jung KH, Jung KY, Lee SK, et al. Treatment strategies for autoimmune encephalitis. Therapeutic Advances in Neurological Disorders. 2018. DOI: https://doi.org/10.1177/1756285617722347

Desena AD, Noland DK, Matevosyan K, King K, Phillips L, Qureshi SS, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-n-methyl-d-aspartate receptor antibody encephalitis: A retrospective review. Journal of Clinical Apheresis. 2015. DOI: https://doi.org/10.1002/jca.21363

Viaccoz A, Desestret V, Ducray F, Picard G, Cavillon G, Rogemond V, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology. 2014; DOI: https://doi.org/10.1212/WNL.0000000000000126

Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AML, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014; DOI: https://doi.org/10.1212/WNL.0000000000000383

Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016; DOI: https://doi.org/10.1212/WNL.0000000000002635

Sonneville R, Venkatesan A, Honnorat J. Understanding auto-immune encephalitis in the ICU. Intensive Care Medicine. 2019. DOI: https://doi.org/10.1007/s00134-019-05773-0

Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018; DOI: https://doi.org/10.1056/NEJMra1708712

Kwan C, Sia A, O’Gorman C. Status epilepticus from GABABR antibody positive encephalitis due to de novo mixed small cell and adenocarcinoma of the prostate. BMJ Case Rep. 2020; DOI: https://doi.org/10.1136/bcr-2020-238172

Alemdar M. Anti-NMDA receptor encephalitis presenting with the new-onset refractory status epilepticus. North Clin Istanbul. 2021;10(3):385–9.

Wang Y, Yu Y, Hu Y, Li Y, Song F, Wang Y. Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis. Front Neurol. 2020; DOI: https://doi.org/10.3389/fneur.2020.00280

Moise AM, Karakis I, Herlopian A, Dhakar M, Hirsch LJ, Cotsonis G, et al. Continuous EEG Findings in Autoimmune Encephalitis. In: Journal of Clinical Neurophysiology. 2021.

Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016; DOI: https://doi.org/10.5698/1535-7597-16.1.48

Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav Reports. 2019; DOI: https://doi.org/10.1016/j.ebr.2019.100326

Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: Proposed recommendations for symptomatic and long-term management. Journal of Neurology, Neurosurgery and Psychiatry. 2021. DOI: https://doi.org/10.1136/jnnp-2020-325302

Dash D, Ihtisham K, Tripathi M, Tripathi M. Proportion and spectrum of movement disorders in adolescent and adult patients of autoimmune encephalitis of non-neoplastic aetiology. J Clin Neurosci. 2019; DOI: https://doi.org/10.1016/j.jocn.2018.10.076

Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical Characteristics and Prognosis of Severe Anti-N-methyl-d-aspartate Receptor Encephalitis Patients. Neurocrit Care. 2018; DOI: https://doi.org/10.1007/s12028-018-0536-6

Kempster P, Monif M. Movement disorders in cell surface antibody mediated autoimmune encephalitis : a meta-analysis. (1).

Honnorat J, Joubert B. Movement disorders in autoimmune encephalitis and paraneoplastic neurological syndromes. Revue Neurologique. 2018. DOI: https://doi.org/10.1016/j.neurol.2018.07.006

Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord. 2017; DOI: https://doi.org/10.1186/s40734-017-0057-z

Ali F, Wijdicks EF. Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU. Neurocritical Care. 2020. DOI: https://doi.org/10.1007/s12028-019-00875-5

Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol. 2011; DOI: https://doi.org/10.1055/s-0031-1271312

Caviness JN. Treatment of Myoclonus. Neurotherapeutics. 2014. DOI: https://doi.org/10.1007/s13311-013-0216-3

Mohammad SS, Dale RC. Principles and approaches to the treatment of immune-mediated movement disorders. European Journal of Paediatric Neurology. 2018. DOI: https://doi.org/10.1016/j.ejpn.2017.11.010

Yan L, Zhang S, Huang X, Tang Y, Wu J. Clinical Study of Autonomic Dysfunction in Patients With Anti-NMDA Receptor Encephalitis. Front Neurol. 2021; DOI: https://doi.org/10.3389/fneur.2021.609750

Diaz-Arias LA, Pardo CA, Probasco JC. Autoimmune Encephalitis in the Intensive Care Unit. Curr Clin Neurol. 2020;249–63. DOI: https://doi.org/10.1007/978-3-030-36548-6_17

Schubert J, Brämer D, Huttner HB, Gerner ST, Fuhrer H, Melzer N, et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol NeuroInflammation. 2019; DOI: https://doi.org/10.1212/NXI.0000000000000514

Rubin DB, Batra A, Vodopivec I, Vaitkevicius H. Autoimmune Encephalitis in Critical Care: Optimizing Immunosuppression. Semin Respir Crit Care Med. 2017; DOI: https://doi.org/10.1055/s-0037-1608771

Rafanelli M, Walsh K, Hamdan MH, Buyan-Dent L. Autonomic dysfunction: Diagnosis and management. In: Handbook of Clinical Neurology. 2019. DOI: https://doi.org/10.1016/B978-0-12-804766-8.00008-X

Lin KL, Lin JJ. Neurocritical care for Anti-NMDA receptor encephalitis. Biomedical Journal. 2020. DOI: https://doi.org/10.1016/j.bj.2020.04.002

Voronova M, Sharko A. Severe Central Hypoventilation Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of the Literature. Cureus. 2022; DOI: https://doi.org/10.7759/cureus.30749

Uy CE, Binks S, Irani SR. Autoimmune encephalitis: Clinical spectrum and management. Practical Neurology. 2021. DOI: https://doi.org/10.1136/practneurol-2020-002567

Bost C, Pascual O, Honnorat J. Autoimmune encephalitis in psychiatric institutions: Current perspectives. Neuropsychiatric Disease and Treatment. 2016. DOI: https://doi.org/10.2147/NDT.S82380

Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: Diagnosis, psychiatric presentation, and treatment. In: American Journal of Psychiatry. 2011. DOI: https://doi.org/10.1176/appi.ajp.2010.10020181

Sarkis RA, Justin Coffey M, Cooper JJ, Hassan I, Lennox B. Anti-N-Methyl-D-aspartate receptor encephalitis: A review of psychiatric phenotypes and management considerations: A report of the american neuropsychiatric association committee on research. J Neuropsychiatry Clin Neurosci. 2019; DOI: https://doi.org/10.1176/appi.neuropsych.18010005

Warren N, O’Gorman C, McKeon G, Swayne A, Blum S, Siskind D. Psychiatric management of anti-NMDAR encephalitis: A cohort analysis. Psychol Med. 2021;

Wang R, Guan HZ, Ren HT, Wang W, Hong Z, Zhou D. CSF findings in patients with anti-N-methyl-d-aspartate receptor-encephalitis. Seizure. 2015; DOI: https://doi.org/10.1016/j.seizure.2015.04.005

Wang Y, Zhang W, Yin J, Lu Q, Yin F, He F, et al. Anti-N-methyl-D-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes. J Neuroimmunol. 2017; DOI: https://doi.org/10.1016/j.jneuroim.2017.09.005

Chi X, Wang W, Huang C, Wu M, Zhang L, Li J, et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis. Acta Neurol Scand. 2017; DOI: https://doi.org/10.1111/ane.12791

Ragland J, Lee K. Critical Care Management and Monitoring of Intracranial Pressure. J Neurocritical Care. 2016; DOI: https://doi.org/10.18700/jnc.160101

Dechambenoit G. AUTOIMMUNE ENCEPHALITIS: A MISSED DIAGNOSTIC AND THERAPEUTIC OPPORTUNITY. African J Neurol Sci. 2018;20(1):66–79.

Thakur KT, Motta M, Asemota AO, Kirsch HL, Benavides DR, Schneider EB, et al. Predictors of outcome in acute encephalitis. Neurology. 2013; DOI: https://doi.org/10.1212/WNL.0b013e3182a2cc6d

Gu Y, Zhong M, He L, Li W, Huang Y, Liu J, et al. Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study. Front Immunol. 2019; DOI: https://doi.org/10.3389/fimmu.2019.02611

Mo Y, Wang L, Zhu L, Li F, Yu G, Luo Y, et al. Analysis of risk factors for a poor prognosis in patients with anti-n-methyl-d-aspartate receptor encephalitis and construction of a prognostic composite score. J Clin Neurol. 2020; DOI: https://doi.org/10.3988/jcn.2020.16.3.438

Qiao S, Wu HK, Liu LL, Zhang RR, Wang ML, Han T, et al. Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study. Front Neurol. 2021; DOI: https://doi.org/10.3389/fneur.2021.642078

Schwarz L, Akbari N, Prüss H, Meisel A, Scheibe F. Clinical characteristics, treatments, outcome, and prognostic factors of severe autoimmune encephalitis in the intensive care unit: Standard treatment and the value of additional plasma cell–depleting escalation therapies for treatment-refractory patients. Eur J Neurol. 2023; DOI: https://doi.org/10.1111/ene.15585

Gitiaux C, Simonnet H, Eisermann M, Leunen D, Dulac O, Nabbout R, et al. Early electro-clinical features may contribute to diagnosis of the anti-NMDA receptor encephalitis in children. Clin Neurophysiol. 2013; DOI: https://doi.org/10.1016/j.clinph.2013.05.023

Ellul MA, Wood G, van Den Tooren H, Easton A, Babu A, Michael BD. Update on the diagnosis and management of autoimmune encephalitis. Clin Med J R Coll Physicians London. 2020; DOI: https://doi.org/10.7861/clinmed.2020-0241

Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: A systematic review. Expert Review of Neurotherapeutics. 2015. DOI: https://doi.org/10.1586/14737175.2015.1115720